Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
PALOMA-3: Subcutaneous Amivantamab + Lazertinib for EGFR+ NSCLC
Lenvatinib Plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and Subsequent Therapy in the CLEAR Trial
First-Line Nivolumab Plus Relatlimab vs Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
CIRCULATE-Japan GALAXY: ctDNA-Based MRD Detection in Colorectal Cancer and Implications for Survival, Treatment, and Risk Stratification
Overall Survival With Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update
Prevent Infusion-Related Reactions With Intravenous Amivantamab: Primary Results From SKIPPirr, a Phase 2 Study
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced NSCLC: Longer Follow-Up of the MARIPOSA Study
Pelabresib in Myelofibrosis: Exploring Disease Modification and Immune Response
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications
Exploring the Dynamics of ctDNA as a Predictive Biomarker of Recurrent Disease in Post-Operative Patients with Colorectal Cancer (CRC)
Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial
ASCO 2024 Updates in the Treatment of Renal Cell Carcinoma and Evolving Data on Non-Clear Cell Renal Cell Carcinoma
DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial
Long-Term Follow-Up from the Phase 1/2 MajesTEC-1 trial of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
Amivantamab plus chemotherapy with or without lazertinib in EGFR- mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated Non-Small-Cell Lung Cancer
Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration
Practical Management of Patients With Relapsed/Refractory Multiple Myeloma Receiving Talquetamab, a GPRC5DxCD3 Bispecific Antibody: Experience in MonumenTAL-1
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Overview of Incidence and Management of CRS Observed With Teclistamab in the MajesTEC-1 Study of Patients With Relapsed/Refractory Multiple Myeloma
Evolving Treatment Landscape in Relapsed/Refractory Multiple Myeloma: MonumenTAL-1 and RedirecTT-1
Nivolumab plus Cabozantinib Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: 3-year Follow-up from the Phase 3 CheckMate 9ER Trial
Amivantamab vs Alternative Therapies in Patients with EGFR Exon 20–Mutated NSCLC
Discussing Post Hoc Analyses from the REACH2 Trial
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ASCENT: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Between The Lines: Once Weekly Selinexor, Carfilzomib & Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients